[{"orgOrder":0,"company":"NeuroSense Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"ISRAEL","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Ciprofloxacin","moa":"DNA gyrase","graph1":"Neurology","graph2":"Phase II","graph3":"NeuroSense Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"NeuroSense Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"NeuroSense Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Burke Therapeutics","sponsor":"Coeptis Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Agreement","leadProduct":"Amlodipine Besylate","moa":"Voltage-gated L-type calcium channel","graph1":"Neurology","graph2":"Approved","graph3":"Burke Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"","sponsorNew":"Burke Therapeutics \/ Coeptis Pharmaceuticals","highestDevelopmentStatusID":"12","companyTruncated":"Burke Therapeutics \/ Coeptis Pharmaceuticals"},{"orgOrder":0,"company":"Virios Therapeutics","sponsor":"ThinkEquity","pharmaFlowCategory":"D","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Public Offering","leadProduct":"Famciclovir","moa":"HSV-1 DNA replication","graph1":"Musculoskeletal","graph2":"Phase II","graph3":"Virios Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Musculoskeletal","amount2New":0.01,"dosageForm":"","sponsorNew":"Virios Therapeutics \/ ThinkEquity","highestDevelopmentStatusID":"8","companyTruncated":"Virios Therapeutics \/ ThinkEquity"},{"orgOrder":0,"company":"NeuroSense Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"ISRAEL","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Ciprofloxacin","moa":"DNA gyrase","graph1":"Neurology","graph2":"Phase II","graph3":"NeuroSense Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"NeuroSense Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"NeuroSense Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Unichem Laboratories Limited","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Celecoxib","moa":"COX-2","graph1":"Musculoskeletal","graph2":"Approved","graph3":"Unichem Laboratories Limited","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Unichem Laboratories Limited \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Unichem Laboratories Limited \/ Not Applicable"},{"orgOrder":0,"company":"NeuroSense Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"ISRAEL","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Ciprofloxacin","moa":"DNA gyrase","graph1":"Neurology","graph2":"Phase II","graph3":"NeuroSense Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"NeuroSense Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"NeuroSense Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Viatris","sponsor":"Astellas Pharma","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Termination","leadProduct":"Celecoxib","moa":"COX-2","graph1":"Immunology","graph2":"Approved","graph3":"Viatris","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Viatris \/ Astellas","highestDevelopmentStatusID":"12","companyTruncated":"Viatris \/ Astellas"},{"orgOrder":0,"company":"Esteve Huayi Pharmaceutical","sponsor":"Kowa Pharmaceuticals America","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"SPAIN","productType":"Small molecule","year":"2021","type":"Agreement","leadProduct":"Celecoxib","moa":"COX-2","graph1":"Neurology","graph2":"Phase III","graph3":"Esteve Huayi Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Esteve Huayi Pharmaceutical \/ Kowa Pharmaceuticals","highestDevelopmentStatusID":"10","companyTruncated":"Esteve Huayi Pharmaceutical \/ Kowa Pharmaceuticals"},{"orgOrder":0,"company":"Dr. Reddy's Laboratories","sponsor":"Ethypharm","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"INDIA","productType":"Small molecule","year":"2021","type":"Acquisition","leadProduct":"Celecoxib","moa":"COX-2","graph1":"Neurology","graph2":"Approved","graph3":"Dr. Reddy\\'s Laboratories","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"Dr. Reddy\\'s Laboratories \/ Ethypharm","highestDevelopmentStatusID":"12","companyTruncated":"Dr. Reddy\\'s Laboratories \/ Ethypharm"},{"orgOrder":0,"company":"Virios Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Famciclovir","moa":"HSV-1 DNA replication","graph1":"Musculoskeletal","graph2":"Phase II","graph3":"Virios Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Virios Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Virios Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Dr. Reddy's Laboratories","sponsor":"BioDelivery Sciences","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"INDIA","productType":"Small molecule","year":"2021","type":"Acquisition","leadProduct":"Celecoxib","moa":"COX-2","graph1":"Neurology","graph2":"Approved","graph3":"Dr. Reddy\\'s Laboratories","amount2":0.02,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0.02,"dosageForm":"Oral Solution","sponsorNew":"Dr. Reddy\\'s Laboratories \/ BioDelivery Sciences","highestDevelopmentStatusID":"12","companyTruncated":"Dr. Reddy\\'s Laboratories \/ BioDelivery Sciences"},{"orgOrder":0,"company":"Dr. Reddy's Laboratories","sponsor":"BioDelivery Sciences","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"INDIA","productType":"Small molecule","year":"2021","type":"Acquisition","leadProduct":"Celecoxib","moa":"COX-2","graph1":"Neurology","graph2":"Approved","graph3":"Dr. Reddy\\'s Laboratories","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"Dr. Reddy\\'s Laboratories \/ BioDelivery Sciences","highestDevelopmentStatusID":"12","companyTruncated":"Dr. Reddy\\'s Laboratories \/ BioDelivery Sciences"},{"orgOrder":0,"company":"Virios Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Famciclovir","moa":"HSV-1 DNA replication","graph1":"Musculoskeletal","graph2":"Phase II","graph3":"Virios Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Virios Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Virios Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Virios Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Famciclovir","moa":"HSV-1 DNA replication","graph1":"Musculoskeletal","graph2":"Phase II","graph3":"Virios Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Virios Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Virios Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Aim ImmunoTech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Rintatolimod","moa":"","graph1":"Oncology","graph2":"Phase II","graph3":"Aim ImmunoTech","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Aim ImmunoTech \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Aim ImmunoTech \/ Not Applicable"},{"orgOrder":0,"company":"NeuroSense Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"ISRAEL","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Ciprofloxacin","moa":"DNA gyrase","graph1":"Neurology","graph2":"Phase II","graph3":"NeuroSense Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"NeuroSense Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"NeuroSense Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"NeuroSense Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"ISRAEL","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Ciprofloxacin","moa":"DNA gyrase","graph1":"Neurology","graph2":"Phase II","graph3":"NeuroSense Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"NeuroSense Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"NeuroSense Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Aim ImmunoTech","sponsor":"Roswell Park Comprehensive Cancer Center","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Rintatolimod","moa":"TLR3","graph1":"Oncology","graph2":"Phase II","graph3":"Aim ImmunoTech","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"Aim ImmunoTech \/ Roswell Park Comprehensive Cancer Center","highestDevelopmentStatusID":"8","companyTruncated":"Aim ImmunoTech \/ Roswell Park Comprehensive Cancer Center"},{"orgOrder":0,"company":"Aim ImmunoTech","sponsor":"Roswell Park Comprehensive Cancer Center","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Rintatolimod","moa":"TLR3","graph1":"Oncology","graph2":"Phase II","graph3":"Aim ImmunoTech","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"Aim ImmunoTech \/ Roswell Park Comprehensive Cancer Center","highestDevelopmentStatusID":"8","companyTruncated":"Aim ImmunoTech \/ Roswell Park Comprehensive Cancer Center"},{"orgOrder":0,"company":"Virios Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Famciclovir","moa":"HSV-1 DNA replication","graph1":"Musculoskeletal","graph2":"Phase II","graph3":"Virios Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Virios Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Virios Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"NeuroSense Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"ISRAEL","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Ciprofloxacin","moa":"DNA gyrase","graph1":"Neurology","graph2":"Phase II","graph3":"NeuroSense Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"NeuroSense Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"NeuroSense Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"NeuroSense Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"ISRAEL","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Ciprofloxacin","moa":"DNA gyrase","graph1":"Neurology","graph2":"Phase II","graph3":"NeuroSense Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"NeuroSense Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"NeuroSense Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Virios Therapeutics","sponsor":"University of Alabama","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Famciclovir","moa":"","graph1":"Musculoskeletal","graph2":"Phase II","graph3":"Virios Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Pill","sponsorNew":"Virios Therapeutics \/ University of Alabama","highestDevelopmentStatusID":"8","companyTruncated":"Virios Therapeutics \/ University of Alabama"},{"orgOrder":0,"company":"NeuroSense Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"ISRAEL","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Ciprofloxacin","moa":"DNA gyrase","graph1":"Neurology","graph2":"Phase II","graph3":"NeuroSense Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"NeuroSense Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"NeuroSense Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"NeuroSense Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"ISRAEL","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Ciprofloxacin","moa":"DNA gyrase","graph1":"Neurology","graph2":"Phase II","graph3":"NeuroSense Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"NeuroSense Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"NeuroSense Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Kowa Pharmaceuticals America","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Celecoxib","moa":"COX-2","graph1":"Neurology","graph2":"Approved","graph3":"Kowa Pharmaceuticals America","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Kowa Pharmaceuticals America \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Kowa Pharmaceuticals America \/ Not Applicable"},{"orgOrder":0,"company":"Aim ImmunoTech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Rintatolimod","moa":"TLR3","graph1":"Oncology","graph2":"Phase II","graph3":"Aim ImmunoTech","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Aim ImmunoTech \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Aim ImmunoTech \/ Not Applicable"},{"orgOrder":0,"company":"Virios Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Valacyclovir","moa":"DNA polymerase","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Virios Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Virios Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Virios Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Collegium Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Celecoxib","moa":"COX-2","graph1":"Neurology","graph2":"Approved","graph3":"Collegium Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Collegium Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Collegium Pharmaceutical \/ Not Applicable"},{"orgOrder":0,"company":"Aim ImmunoTech","sponsor":"Roswell Park Comprehensive Cancer Center","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Rintatolimod","moa":"TLR3","graph1":"Oncology","graph2":"Phase II","graph3":"Aim ImmunoTech","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Aim ImmunoTech \/ Roswell Park Comprehensive Cancer Center","highestDevelopmentStatusID":"8","companyTruncated":"Aim ImmunoTech \/ Roswell Park Comprehensive Cancer Center"},{"orgOrder":0,"company":"Virios Therapeutics","sponsor":"ThinkEquity","pharmaFlowCategory":"D","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Public Offering","leadProduct":"Famciclovir","moa":"HSV-1 DNA polymerase","graph1":"Musculoskeletal","graph2":"Phase II","graph3":"Virios Therapeutics","amount2":0.01,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Musculoskeletal","amount2New":0.01,"dosageForm":"Tablet","sponsorNew":"Virios Therapeutics \/ ThinkEquity","highestDevelopmentStatusID":"8","companyTruncated":"Virios Therapeutics \/ ThinkEquity"},{"orgOrder":0,"company":"Virios Therapeutics","sponsor":"ThinkEquity","pharmaFlowCategory":"D","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Public Offering","leadProduct":"Famciclovir","moa":"HSV-1 DNA polymerase","graph1":"Musculoskeletal","graph2":"Phase II","graph3":"Virios Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Musculoskeletal","amount2New":0.01,"dosageForm":"Pill","sponsorNew":"Virios Therapeutics \/ ThinkEquity","highestDevelopmentStatusID":"8","companyTruncated":"Virios Therapeutics \/ ThinkEquity"},{"orgOrder":0,"company":"Virios Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Famciclovir","moa":"HSV-1 DNA polymerase","graph1":"Musculoskeletal","graph2":"Phase II","graph3":"Virios Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Pill","sponsorNew":"Virios Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Virios Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"NeuroSense Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"ISRAEL","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Ciprofloxacin","moa":"DNA gyrase","graph1":"Neurology","graph2":"Phase II","graph3":"NeuroSense Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet, Extended Release","sponsorNew":"NeuroSense Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"NeuroSense Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"NeuroSense Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"ISRAEL","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Ciprofloxacin","moa":"DNA gyrase","graph1":"Neurology","graph2":"Phase II","graph3":"NeuroSense Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet, Extended Release","sponsorNew":"NeuroSense Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"NeuroSense Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"NeuroSense Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"ISRAEL","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Ciprofloxacin","moa":"DNA gyrase","graph1":"Neurology","graph2":"Phase II","graph3":"NeuroSense Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"NeuroSense Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"NeuroSense Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"NeuroSense Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"ISRAEL","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Ciprofloxacin","moa":"","graph1":"Neurology","graph2":"Phase II","graph3":"NeuroSense Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"NeuroSense Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"NeuroSense Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"NeuroSense Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"ISRAEL","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Ciprofloxacin","moa":"","graph1":"Neurology","graph2":"Phase II","graph3":"NeuroSense Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"NeuroSense Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"NeuroSense Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Virios Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Famciclovir","moa":"","graph1":"Musculoskeletal","graph2":"Phase II","graph3":"Virios Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Pill","sponsorNew":"Virios Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Virios Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"NeuroSense Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"ISRAEL","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Ciprofloxacin","moa":"","graph1":"Neurology","graph2":"Phase II","graph3":"NeuroSense Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet, Extended Release","sponsorNew":"NeuroSense Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"NeuroSense Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Undisclosed","sponsor":"Scilex Holding Company","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Small molecule","year":"2023","type":"Acquisition","leadProduct":"Celecoxib","moa":"","graph1":"Neurology","graph2":"Approved","graph3":"Undisclosed","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Undisclosed \/ Scilex Holding Company","highestDevelopmentStatusID":"12","companyTruncated":"Undisclosed \/ Scilex Holding Company"},{"orgOrder":0,"company":"Virios Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Valacyclovir","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Virios Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Virios Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Virios Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Scilex Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Celecoxib","moa":"","graph1":"Neurology","graph2":"Approved","graph3":"Scilex Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Scilex Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Scilex Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"NeuroSense Therapeutics","sponsor":"Massachusetts General Hospital","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"ISRAEL","productType":"Small molecule","year":"2023","type":"Collaboration","leadProduct":"Ciprofloxacin","moa":"","graph1":"Neurology","graph2":"Phase II","graph3":"NeuroSense Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet, Extended Release","sponsorNew":"NeuroSense Therapeutics \/ Massachusetts General Hospital","highestDevelopmentStatusID":"8","companyTruncated":"NeuroSense Therapeutics \/ Massachusetts General Hospital"},{"orgOrder":0,"company":"Virios Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Famciclovir","moa":"","graph1":"Musculoskeletal","graph2":"Phase II","graph3":"Virios Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Pill","sponsorNew":"Virios Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Virios Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"NeuroSense Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"ISRAEL","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Celecoxib","moa":"","graph1":"Neurology","graph2":"Preclinical","graph3":"NeuroSense Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"","sponsorNew":"NeuroSense Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"NeuroSense Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"NeuroSense Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"ISRAEL","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Ciprofloxacin","moa":"","graph1":"Neurology","graph2":"Phase II","graph3":"NeuroSense Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet, Extended Release","sponsorNew":"NeuroSense Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"NeuroSense Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"NeuroSense Therapeutics","sponsor":"Biogen","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"ISRAEL","productType":"Small molecule","year":"2023","type":"Collaboration","leadProduct":"Ciprofloxacin","moa":"","graph1":"Neurology","graph2":"Phase II","graph3":"NeuroSense Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet, Extended Release","sponsorNew":"NeuroSense Therapeutics \/ Biogen","highestDevelopmentStatusID":"8","companyTruncated":"NeuroSense Therapeutics \/ Biogen"},{"orgOrder":0,"company":"NeuroSense Therapeutics","sponsor":"Alliance Global Partners","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"ISRAEL","productType":"Small molecule","year":"2023","type":"Public Offering","leadProduct":"Ciprofloxacin","moa":"","graph1":"Neurology","graph2":"Phase II","graph3":"NeuroSense Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet, Extended Release","sponsorNew":"NeuroSense Therapeutics \/ Alliance Global Partners","highestDevelopmentStatusID":"8","companyTruncated":"NeuroSense Therapeutics \/ Alliance Global Partners"},{"orgOrder":0,"company":"Virios Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Valacyclovir","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Virios Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Virios Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Virios Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Virios Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Famciclovir","moa":"","graph1":"Musculoskeletal","graph2":"Phase II","graph3":"Virios Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Pill","sponsorNew":"Virios Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Virios Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"MedinCell","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"FRANCE","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Celecoxib","moa":"","graph1":"Neurology","graph2":"Phase III","graph3":"MedinCell","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"MedinCell \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"MedinCell \/ Not Applicable"},{"orgOrder":0,"company":"Aim ImmunoTech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Rintatolimod","moa":"","graph1":"Oncology","graph2":"Phase II","graph3":"Aim ImmunoTech","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Aim ImmunoTech \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Aim ImmunoTech \/ Not Applicable"},{"orgOrder":0,"company":"Virios Therapeutics","sponsor":"JonesTrading Institutional Services","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Small molecule","year":"2023","type":"Termination","leadProduct":"Valacyclovir","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Virios Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Virios Therapeutics \/ JonesTrading Institutional Services","highestDevelopmentStatusID":"8","companyTruncated":"Virios Therapeutics \/ JonesTrading Institutional Services"},{"orgOrder":0,"company":"NeuroSense Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"ISRAEL","productType":"Small molecule","year":"2023","type":"Public Offering","leadProduct":"Ciprofloxacin","moa":"","graph1":"Neurology","graph2":"Phase II","graph3":"NeuroSense Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet, Extended Release","sponsorNew":"NeuroSense Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"NeuroSense Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"NeuroSense Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"ISRAEL","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Ciprofloxacin","moa":"","graph1":"Neurology","graph2":"Phase II","graph3":"NeuroSense Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet, Extended Release","sponsorNew":"NeuroSense Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"NeuroSense Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"NeuroSense Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"ISRAEL","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Ciprofloxacin","moa":"","graph1":"Neurology","graph2":"Phase II","graph3":"NeuroSense Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet, Extended Release","sponsorNew":"NeuroSense Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"NeuroSense Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Virios Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Valacyclovir","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Virios Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Virios Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Virios Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Virios Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Valacyclovir","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Virios Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Virios Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Virios Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"NeuroSense Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"ISRAEL","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Ciprofloxacin","moa":"","graph1":"Neurology","graph2":"Phase II","graph3":"NeuroSense Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet, Extended Release","sponsorNew":"NeuroSense Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"NeuroSense Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"NeuroSense Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"ISRAEL","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Ciprofloxacin","moa":"","graph1":"Neurology","graph2":"Phase II","graph3":"NeuroSense Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet, Extended Release","sponsorNew":"NeuroSense Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"NeuroSense Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Scilex Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Celecoxib","moa":"","graph1":"Neurology","graph2":"Approved","graph3":"Scilex Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Scilex Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Scilex Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Scilex Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Celecoxib","moa":"","graph1":"Neurology","graph2":"Approved","graph3":"Scilex Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Scilex Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Scilex Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"NeuroSense Therapeutics","sponsor":"Lonza Group","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"ISRAEL","productType":"Small molecule","year":"2024","type":"Collaboration","leadProduct":"Ciprofloxacin","moa":"","graph1":"Neurology","graph2":"Phase II","graph3":"NeuroSense Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet, Extended Release","sponsorNew":"NeuroSense Therapeutics \/ Lonza Group","highestDevelopmentStatusID":"8","companyTruncated":"NeuroSense Therapeutics \/ Lonza Group"},{"orgOrder":0,"company":"Genetika","sponsor":"NeuroSense Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Small molecule","year":"2024","type":"Collaboration","leadProduct":"Ciprofloxacin","moa":"","graph1":"Neurology","graph2":"Phase II","graph3":"Genetika","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet, Extended Release","sponsorNew":"Genetika \/ NeuroSense Therapeutics","highestDevelopmentStatusID":"8","companyTruncated":"Genetika \/ NeuroSense Therapeutics"},{"orgOrder":0,"company":"NeuroSense Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"ISRAEL","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Ciprofloxacin","moa":"","graph1":"Neurology","graph2":"Phase II","graph3":"NeuroSense Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet, Extended Release","sponsorNew":"NeuroSense Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"NeuroSense Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Virios Therapeutics","sponsor":"Maxim Group","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Small molecule","year":"2024","type":"Public Offering","leadProduct":"Valacyclovir","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Virios Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Virios Therapeutics \/ Maxim Group","highestDevelopmentStatusID":"6","companyTruncated":"Virios Therapeutics \/ Maxim Group"},{"orgOrder":0,"company":"NeuroSense Therapeutics","sponsor":"PhaseV","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"ISRAEL","productType":"Small molecule","year":"2024","type":"Partnership","leadProduct":"Ciprofloxacin","moa":"","graph1":"Neurology","graph2":"Phase II","graph3":"NeuroSense Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"","sponsorNew":"NeuroSense Therapeutics \/ PhaseV","highestDevelopmentStatusID":"8","companyTruncated":"NeuroSense Therapeutics \/ PhaseV"},{"orgOrder":0,"company":"NeuroSense Therapeutics","sponsor":"NeuraLight","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"ISRAEL","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Ciprofloxacin","moa":"","graph1":"Technology","graph2":"Approved","graph3":"NeuroSense Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Technology","amount2New":0.10000000000000001,"dosageForm":"","sponsorNew":"NeuroSense Therapeutics \/ NeuraLight","highestDevelopmentStatusID":"12","companyTruncated":"NeuroSense Therapeutics \/ NeuraLight"},{"orgOrder":0,"company":"Virios Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Valacyclovir","moa":"","graph1":"Technology","graph2":"Approved","graph3":"Virios Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Technology","amount2New":0.10000000000000001,"dosageForm":"","sponsorNew":"Virios Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Virios Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"NeuroSense Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"ISRAEL","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Ciprofloxacin","moa":"","graph1":"Technology","graph2":"Approved","graph3":"NeuroSense Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Technology","amount2New":0.10000000000000001,"dosageForm":"","sponsorNew":"NeuroSense Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"NeuroSense Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"NeuroSense Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"ISRAEL","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Ciprofloxacin","moa":"","graph1":"Technology","graph2":"Approved","graph3":"NeuroSense Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Technology","amount2New":0.10000000000000001,"dosageForm":"","sponsorNew":"NeuroSense Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"NeuroSense Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"NeuroSense Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"ISRAEL","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Ciprofloxacin","moa":"","graph1":"Technology","graph2":"Approved","graph3":"NeuroSense Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Technology","amount2New":0.10000000000000001,"dosageForm":"","sponsorNew":"NeuroSense Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"NeuroSense Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"NeuroSense Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"ISRAEL","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Ciprofloxacin","moa":"","graph1":"Technology","graph2":"Approved","graph3":"NeuroSense Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Technology","amount2New":0.10000000000000001,"dosageForm":"","sponsorNew":"NeuroSense Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"NeuroSense Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"NeuroSense Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"ISRAEL","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Ciprofloxacin","moa":"","graph1":"Technology","graph2":"Approved","graph3":"NeuroSense Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Technology","amount2New":0.10000000000000001,"dosageForm":"","sponsorNew":"NeuroSense Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"NeuroSense Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Dogwood Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Valacyclovir","moa":"","graph1":"Technology","graph2":"Approved","graph3":"Dogwood Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Technology","amount2New":0.10000000000000001,"dosageForm":"","sponsorNew":"Dogwood Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Dogwood Therapeutics \/ Not Applicable"}]
Find Clinical Drug Pipeline Developments & Deals for Celecoxib
Filters
×
FILTER:
Company Name
Year
DEALS // DEV.
Country
Sponsor
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target